CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy ...
The RECIST guidelines provide a standardized approach for evaluating the response of cancer to treatment, allowing for consistent comparison of treatment efficacy across different therapies and ...
This episode, titled ‘Navigating Benefit Design and Utilization Management in ATTR-CM,’ features the experts examining how ...
-- Durable disease control and quality-of-life improvements for patients with ISM in the PIONEER trial -- -- Prolonged survival, including in the first-line treatment setting, for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results